Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer

Neoplasia

Volumn 10, Issue 10, 2008, Pages 1057-1065

  Bayani, Jane ^a,b   Paderova, Jana ^b   Murphy, Joan ^c   Rosen, Barry ^c   Zielenska, Maria ^a,d   Squire, Jeremy A ^a,b,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CENTROSOME; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DIPLOIDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; MITOSIS; NUMERICAL CHROMOSOME ABERRATION; OVARY CARCINOMA; PRIORITY JOURNAL; STRUCTURAL CHROMOSOME ABERRATION; TETRAPLOIDY; TRIPLOIDY;

EID: 54249119072     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08584     Document Type: Article

References (55)

1. Taetle R, Aickin M, Yang JM, Panda L, Emerson J, Roe D, Adair L, Thompson F, Liu Y, Wisner L, et al. (1999). Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer 25, 290-300.
2. Taetle R, Aickin M, Panda L, Emerson J, Roe D, Thompson F, Davis J, Trent J, and Alberts D (1999). Chromosome abnormalities in ovarian adenocarcinoma: II. Prognostic impact of nonrandom chromosome abnormalities in 244 cases. Genes Chromosomes Cancer 25, 46-52.
3. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, et al. (2001). Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 61, 5895-5904.
4. Bayani J, Brenton JD, Macgregor PF, Beheshti B, Albert M, Nallainathan D, Karaskova J, Rosen B, Murphy J, Laframboise S, et al. (2002). Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res 62, 3466-3476.
5. Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, et al. (2005). High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 7, 603-613.
6. Gollin SM (2005). Mechanisms leading to chromosomal instability. Semin Cancer Biol 15, 33-42.
7. Gorringe KL, Chin SF, Pharoah P, Staines JM, Oliveira C, Edwards PA, and Caldas C (2005). Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. Carcinogenesis 26, 923-930.
8. Lengauer C, Kinzler KW, and Vogelstein B (1997). Genetic instability in colorectal cancers. Nature 386, 623-627.
9. Rajagopalan H, Nowak MA, Vogelstein B, and Lengauer C (2003). The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 3, 695-701.
10. Muleris M, Chalastanis A, Meyer N, Lae M, Dutrillaux B, Sastre-Garau X, Hamelin R, Flejou JF, and Duval A (2008). Chromosomal instability in near-diploid colorectal cancer: a link between numbers and structure. PLoS ONE 3, e1632.
11. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, and Vogelstein B (1998). Mutations of mitotic checkpoint genes in human cancers [see comments]. Nature 392, 300-303.
12. Kops GJ, Weaver BA, and Cleveland DW (2005). On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5, 773-785.
13. Hoeijmakers JH (2001). Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374.
14. Bayani J, Selvarajah S, Maire G, Vukovic B, Al-Romaih K, Zielenska M, and Squire JA (2006). Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Semin Cancer Biol 17, 5-18.
15. Stewart SA and Weinberg RA (2000). Telomerase and human tumorigenesis. Semin Cancer Biol 10, 399-406.
16. Nigg EA (2002). Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2, 815-825.
17. Stewart ZA, Leach SD, and Pietenpol JA (1999). P21(WAF1/CIP1) inhibition of cyclin E/cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol Cell Biol 19, 205-215.
18. Andreassen PR, Lohez OD, Lacroix FB, and Margolis RL (2001). Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in g1. Mol Biol Cell 12, 1315-1328.
19. Skoufias DA, Andreassen PR, Lacroix FB, Wilson L, and Margolis RL (2001). Mammalian MAD2 and BUB1/BUBR1 recognize distinct spindle-attachment and kinetochore-tension checkpoints. Proc Natl Acad Sci USA 98, 4492-4497.
20. Saunders W (2005). Centrosomal amplification and spindle multipolarity in cancer cells. Semin Cancer Biol 15, 25-32.
21. Wan TS, Martens UM, Poon SS, Tsao SW, Chan LC, and Lansdorp PM (1999). Absence or low number of telomere repeats at junctions of dicentric chromosomes. Genes Chromosomes Cancer 24, 83-86.
22. Shaffer LG and Tommerup N (2005). An International System for Human Cytogenetic Nomenclature (2005). Basel, Switzerland: Karger Publishers.
23. Al-Romaih K, Bayani J, Vorobyova J, Karaskova J, Park PC, Zielenska M, and Squire JA (2003). Chromosomal instability in osteosarcoma and its association with centrosome abnormalities. Cancer Genet Cytogenet 144, 91-99.
24. Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, and Doxsey SJ (1998). Centrosome defects and genetic instability in malignant tumors. Cancer Res 58, 3974-3985.
25. Murnane JP (2006). Telomeres and chromosome instability. DNA Repair (Amst) 5, 1082-1092.
26. Gisselsson D and Hoglund M (2005). Connecting mitotic instability and chromosome aberrations in cancer - can telomeres bridge the gap? Semin Cancer Biol 15, 13-23.
27. Grigorova M, Staines JM, Ozdag H, Caldas C, and Edwards PA (2004). Possible causes of chromosome instability: comparison of chromosomal abnormalities in cancer cell lines with mutations in BRCA1, BRCA2, CHK2 and BUB1. Cytogenet Genome Res 104, 333-340.
28. Doxsey S (2002). Duplicating dangerously: linking centrosome duplication and aneuploidy. Mol Cell 10, 439-440.
29. Pihan GA and Doxsey SJ (1999). The mitotic machinery as a source of genetic instability in cancer. Semin Cancer Biol 9, 289-302.
30. Wang Q, Hirohashi Y, Furuuchi K, Zhao H, Liu Q, Zhang H, Murali R, Berezov A, Du X, Li B, et al. (2004). The centrosome in normal and transformed cells. DNA Cell Biol 23, 475-489.
31. Quintyne NJ, Reing JE, Hoffelder DR, Gollin SM, and Saunders WS (2005). Spindle multipolarity is prevented by centrosomal clustering. Science 307, 127-129.
32. Rebacz B, Larsen TO, Clausen MH, Ronnest MH, Loffler H, Ho AD, and Kramer A (2007). Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Cancer Res 67, 6342-6350.
33. Jones RN (2005). McClintock's controlling elements: the full story. Cytogenet Genome Res 109, 90-103.
34. Lim G, Karaskova J, Beheshti B, Vukovic B, Bayani J, Selvarajah S, Watson SK, Lam WL, Zielenska M, and Squire JA (2005). An integrated MBand and submegabase resolution tiling set (SMRT) CGH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage-fusion-bridge cycle events in osteosarcoma. Genes Chromosomes Cancer 42, 392-403.
35. Selvarajah S, Yoshimoto M, Park PC, Maire G, Paderova J, Bayani J, Lim G, Al-Romaih K, Squire JA, and Zielenska M (2006). The breakage-fusion-bridge (BFB) cycle as a mechanism for generating genetic heterogeneity in osteosarcoma. Chromosoma 115, 459-467.
36. Vukovic B, Beheshti B, Park P, Lim G, Bayani J, Zielenska M, and Squire JA (2007). Correlating breakage-fusion-bridge events with the overall chromosomal instability and in vitro karyotype evolution in prostate cancer. Cytogenet Genome Res 116, 1-11.
37. Gisselsson D, Lv M, Tsao SW, Man C, Jin C, Hoglund M, Kwong YL, and Jin Y (2005). Telomere-mediated mitotic disturbances in immortalized ovarian epithelial cells reproduce chromosomal losses and breakpoints from ovarian carcinoma. Genes Chromosomes Cancer 42, 22-33.
38. Bayani J, Zielenska M, Pandita A, Al-Romaih K, Karaskova J, Harrison K, Bridge JA, Sorensen P, Thorner P, and Squire JA (2003). Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 36, 7-16.
39. Zielenska M, Bayani J, Pandita A, Toledo S, Marrano P, Andrade J, Petrilli A, Thorner P, Sorensen P, and Squire JA (2001). Comparative genomic hybridization analysis identifies gains of 1p35 approximately p36 and chromosome 19 in osteosarcoma. Cancer Genet Cytogenet 130, 14-21.
40. Selvarajah S, Yoshimoto M, Maire G, Paderova J, Bayani J, Squire JA, and Zielenska M (2007). Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization. Cancer Genet Cytogenet 179, 52-61.
41. Prat J, Ribe A, and Gallardo A (2005). Hereditary ovarian cancer. Hum Pathol 36, 861-870.
42. Deng CX (2006). BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 34, 1416-1426.
43. Weaver Z, Montagna C, Xu X, Howard T, Gadina M, Brodie SG, Deng CX, and Ried T (2002). Mammary tumors in mice conditionally mutant for BRCA1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 21, 5097-5107.
44. Deng CX and Wang RH (2003). Roles of BRCA1 in DNA damage repair: a link between development and cancer. Hum Mol Genet 12 Spec No 1, R113-R123.
45. Bae I, Rih JK, Kim HJ, Kang HJ, Haddad B, Kirilyuk A, Fan S, Avantaggiati ML, and Rosen EM (2005). BRCA1 regulates gene expression for orderly mitotic progression. Cell Cycle 4, 1641-1666.
46. Kristensen GB, Kildal W, Abeler VM, Kaern J, Vergote I, Trope CG, and Danielsen HE (2003). Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Ann Oncol 14, 1494-1500.
47. Resnik E, Trujillo YP, and Taxy JB (1997). Long-term survival and DNA ploidy in advanced epithelial ovarian cancer. J Surg Oncol 64, 299-303.
48. Kimmig R, Wimberger P, Hillemanns P, Kapsner T, Caspari C, and Hepp H (2002). Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells. Gynecol Oncol 84, 21-31.
49. Prasad M, Bernardini M, Tsalenko A, Marrano P, Paderova J, Lee CH, Ben-Dor A, Barrett MT, and Squire JA (2008). High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells. Genes Chromosomes Cancer 47, 427-436.
50. Zhang L, Huang J, Yang N, Greshock J, Liang S, Hasegawa K, Giannakakis A, Poulos N, O'Brien-Jenkins A, Katsaros D, et al. (2007). Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 13, 5314-5321.
51. Barbarotto E, Schmittgen TD, and Calin GA (2008). MicroRNAs and cancer: profile, profile, profile. Int J Cancer 122, 969-977.
52. Calin GA and Croce CM (2007). Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest 117, 2059-2066.
53. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al. (2007). MicroRNA signatures in human ovarian cancer. Cancer Res 67, 8699-8707.
54. Ailles LE and Weissman IL (2007). Cancer stem cells in solid tumors. Curr Opin Biotechnol 18, 460-466.
55. Dean M, Fojo T, and Bates S (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-284.